Cancer Clinical Trial
— PERCSOfficial title:
Personalised Exercise Rehabilitation for Cancer Survivorship
Verified date | November 2023 |
Source | University of Dublin, Trinity College |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
There is strong evidence that exercise can help improve physical and mental wellbeing after treatment for cancer. However, at present, people with cancer in Ireland are not given the opportunity to have an individual assessment of their physical and psychological wellbeing as part of standard care and are not routinely prescribed exercise-based rehabilitation. The researchers will run and evaluate a system to i. assess physical and psychological wellbeing of people who have completed cancer treatment, ii. apply a rehabilitation triage system, based on findings of the assessment, iii. refer participants to one of three rehabilitation pathways, as per outcome of the triage process. Rehabilitation pathways are as follows: 1. Participants who are currently active and have no cancer-specific impairments will receive advice from the physiotherapist on maintaining their current levels of activity. 2. Participants who are not active and have no cancer-specific impairments will be referred to a suitable community-based exercise programme. This programme must contain both resistance and aerobic training and should have some level of supervision from a fitness professional. 3. Participants who are not active and have ongoing cancer-specific impairments will be referred to an oncology specialist physiotherapist, funded through this work, at St James's Hospital for assessment and treatment. All participants will be encouraged to visit www.cancerrehabilitation.ie for information through out the study. Participants will be reassessed 12 weeks after the initial assessment. The implementation of this system will be evaluated using the RE-AIM framework.
Status | Completed |
Enrollment | 70 |
Est. completion date | October 31, 2023 |
Est. primary completion date | September 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients will be eligible to participate if they: 1. Were diagnosed with cancer at St James's Hospital since March 2020 2. Have completed adjuvant chemotherapy and/or radiotherapy 3. Are at least 6 weeks post-surgery 4. Do not show signs of recurrent or metastatic disease at the time of enrolment 5. Are over the age of 18 years Exclusion Criteria: Anyone who is unable to provide informed consent Any person with known or signs or symptoms suggestive of cardiovascular, metabolic or renal disease will require medical clearance from a physiotherapist or medical professional prior to participation, based on criteria outlined in the Safety Reference Guide to support the safe delivery of exercise services to people with cancer by Santa Mina et al. (2018). Preparticipation screening will be completed in accordance with the American College of Sports Medicine Preparticipation health screening recommendations. |
Country | Name | City | State |
---|---|---|---|
Ireland | Clinical Research Facility, St James's Hospital | Dublin |
Lead Sponsor | Collaborator |
---|---|
University of Dublin, Trinity College | Irish Cancer Society, La Trobe University, Melbourne, Australia, National Cancer Control Programme, Ireland, Royal College of Surgeons, Ireland, Technological University Dublin, Ireland, Trinity St James's Cancer Institute, Dublin, Ireland, Wellcome Trust-HRB Clinical Research Facility, St James's Hospital, Dublin, Ireland |
Ireland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | RE-AIM Framework | Evaluation of system Reach, Effectiveness, Adoption, Implementation, Maintenance | Data reported by 12 months | |
Primary | Percentage of patients on Prehabilitation list which are eligible for the study | Referral - Eligible referral rate from prehabilitation group | Data reported by 12 months | |
Primary | The percentage of referrals to the study from clinical team which are eligible for the study | Referral - Eligible referral rate from clinical teams | Data reported by 12 months | |
Primary | Percentage of people enrolled in study who have received both recruitment letter and phone call | Enrolment rate | Data reported by 12 months | |
Primary | Percentage of people attending scheduled assessments at i. T0 and ii. T1 | Assessment completion rate | Data reported by 12 months | |
Primary | Percentage of people who attended assessment who proceed to attend level 2 or level 3 referral service | Attrition rate - referrals | Data reported by 12 months | |
Primary | Percentage of people who attended T0 assessment that attend T1 assessment | Attrition rate - assessments | Data reported by 12 months | |
Primary | i. Time from assessment to referral being sent ii. Percentage of referral accepted at initial site iii. Time from referral sent to initial appointment | Referral outcome - time frame and acceptance | Data reported by 12 months | |
Primary | i. Percentage of people triaged to each level (1, 2 or 3) ii. Percentage triaged to another level after initial triage and why | Triage results | Data reported by 12 months | |
Primary | Number and nature of adverse events occurring in assessment process | Adverse events | Data reported by 12 months | |
Primary | Information related to feasibility gathered from semi-structured interviews with participants | Qualitative feasibility | Data reported by 12 months | |
Secondary | International Physical Activity Questionnaire | Physical activity levels assessment Health Behaviour and Stages of Change Questionnaire Self-Efficacy for Exercise Scale | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Health Behaviour and Stages of Change Questionnaire | Readiness to change assessment Health Behaviour and Stages of Change Questionnaire Self-Efficacy for Exercise Scale | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Self-efficacy for exercise scale | Physical activity self efficacy assessment Health Behaviour and Stages of Change Questionnaire Self-Efficacy for Exercise Scale | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Patient specific funcational scale | Self-reported function. Scale from 0 - 10, higher score indicates higher perceived ability to do task | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Timed Up and Go | Falls Risk | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Hand grip strength | Muscle strength | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | 30 second Sit-to-Stand | Funcational lower body strength | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Six minute walk test | aerobic capacity &endurance | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Height | Anthropometrics | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Weight | Anthropometrics | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Waist Circumference | Anthropometrics | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Mid-arm Circumference | Anthropometrics | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Mini Nutritional Assessment | Nutritional | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | EOCG-PS | Performance status | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC- QLQ-C30) | Quality of life | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Multidimensional Fatigue Inventory (MFI-20) | Fatigue | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Hospital Anxiety and Depression Scale (HADS) | Anxiety & depression; Scale from 0 - 21, higher score indicates higher levels of anxiety and/or depression. | T0 assessment, T1 (+12 weeks from T0 assessment); data reported by 12 months | |
Secondary | Sociodemographic details | T0 assessment; data reported by 12 months | ||
Secondary | Medical history | T0 assessment; data reported by 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|